References
Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ (2010) Surgical treatment of gastric cancer: 15-year follow-up results of the randomized nationwide Dutch D1D2 trial. Lancet Oncol 11(5):439–449. doi:10.1016/S1470-2045(10)70070-X
Sano T (2010) Evaluation of the gastric cancer treatment guidelines of the Japanese Gastric Cancer Association. Gan To Kagaku Ryoho 37(4):582–586
Katsios C, Baltogiannis G, Roukos DH (2011) Progress, challenges and new genome-based concepts in the multidisciplinary treatment of gastric cancer. Expert Rev Anticancer Ther 11(4):503–506. doi:10.1586/era.11.15
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW (2013) Cancer genome landscapes. Science 339(6127):1546–1558. doi:10.1126/science.1235122
ENCODE Project Consortium, Dunham I, Kundaje A, Aldred SF et al (2012) An integrated encyclopedia of DNA elements in the human genome. Nature 489(7414):57–74. doi:10.1038/nature11247
Zhao XF, Jeong O, Jung MR, Ryu SY, Park YK (2013) A propensity score-matched case-control comparative study of laparoscopic and open extended (D2) lymph node dissection for distal gastric carcinoma. Surg Endosc 27(8):2792–2800. doi:10.1007/s00464-013-2809-7
Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22(5):1405–1406. doi:10.1007/s00464-008-9796-0
Nikiteas N, Roukos D, Kouraklis G (2011) Robotic versus laparoscopic surgery: perspectives for tailoring an optimal surgical option. Expert Rev Med Dev 8(3):295–298. doi:10.1586/erd.11.15
Ziogas D, Polychronidis A, Kanellos I, Roukos D (2009) Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true? Ann Surg 249(4):695–696 (author reply 697). doi:10.1097/SLA.0b013e31819f26e9
Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22(6):1553–1555. doi:10.1007/s00464-008-9869-0
Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. Ann Surg 250(2):349–350 (author reply 350). doi:10.1097/SLA.0b013e3181b1e890
Roukos DH (2009) Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg 250:650–651 (author reply 651). doi:10.1097/SLA.0b013e3181b970dd
Liakakos T, Roukos DH (2008) Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer? Surg Endosc 22(5):1402–1404. doi:10.1007/s00464-008-9890-3
Roukos DH (2011) Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharma J 11(2):81–92. doi:10.1038/tpj.2010.81
Stamatoyannopoulos JA (2012) What does our genome encode? Genome Res 22(9):1602–1611. doi:10.1101/gr.146506.112.
Roukos DH (2013) Genome network medicine: innovation to overcome huge challenges in cancer therapy. Wiley Interdiscip Rev Syst Biol Med. doi:10.1002/wsbm.1254
Roukos DH (2013) Genome network medicine: new diagnostics and predictive tools. Expert Rev Mol Diagn 13(7):643–646. doi:10.1586/14737159.2013.820540
Roukos DH, Baltogiannis GG, Katsouras CS, Bechlioulis A, Naka KK, Batsis C, Liakakos T, Michalis LK (2014) Novel next-generation sequencing and networks-based therapeutic targets: realistic and more effective drug design and discovery. Curr Pharm Des 20(1):11–22. doi:10.2174/13816128113199990385
Roukos D (2013) Integrative deep-sequencing analysis of cancer samples: discoveries and clinical challenges. Pharmacogenomics J 13(3):205–208. doi:10.1038/tpj.2012.51
Roukos DH (2010) Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev Med Devices 7(6):723–726
Roukos DH (2011) Cancer genome explosion and systems biology: impact on surgical oncology? Ann Surg Oncol 18(1):12–15
Roukos DH (2011) Chromatin: a key player in complex gene regulation and future cancer therapeutics. Epigenomics 3(4):395–399
Roukos DH (2011) Networks medicine: from reductionism to evidence of complex dynamic biomolecular interactions. Pharmacogenomics 12(5):695–698
Roukos DH (2011) Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets. Expert Rev Med Devices 8(2):123–126
Roukos DH (2011) “Big” science: genome regulatory networks and novel molecular tools to improve health. Expert Rev Mol Diagn 11(2):123–126
Roukos DH (2011) Translating epigenetics into an anticancer drug pipeline for solid tumors. Expert Rev Med Devices 8(4):409–413
Roukos DH (2010) Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. J Clin Oncol 28(17):e279–e280 author reply e282–e283
Roukos DH (2012) Spatiotemporal individual genome code-lifestyle network: revolutionizing personal diagnostics. Expert Rev Mol Diagn 9(3):215–218
Roukos DH (2012) Differential signalling transduction networks for clinical robustness. Expert Rev Proteomics 9(2):111–114
Roukos DH (2012) Biotechnological, genomics and systems-synthetic biology revolution: redesigning genetic code for a pragmatic systems medicine. Expert Rev Med Devices 9(2):97–101
Roukos DH (2012) Longevity with systems medicine? Epigenome, genome and environment interactions network. Epigenomics 4(2):119–123
Roukos DH (2012) Disrupting cancer cells’ biocircuits with interactome-based drugs: is ‘clinical’ innovation realistic? Expert Rev Proteomics 9(4):349–353
Ku CS, Roukos DH (2013) From next-generation sequencing to nanopore sequencing technology: paving the way to personalized genomic medicine. Expert Rev Med Devices 10(1):1–6. doi:10.1586/erd.12.63
Ku CS, Cooper DN, Wu M, Roukos DH, Pawitan Y, Soong R, Iacopetta B (2012) Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X. Mod Pathol 25(8):1055–1068. doi:10.1038/modpathol.2012.62
Ku CS, Polychronakos C, Tan EK, Naidoo N, Pawitan Y, Roukos DH, Mort M, Cooper DN (2013) A new paradigm emerges from the study of de novo mutations in the context of neurodevelopmental disease. Mol Psychiatry 8(2):141–153. doi:10.1038/mp.2012.58
Ku CS, Cooper DN, Iacopetta B, Roukos DH (2013) Integrating next-generation sequencing into the diagnostic testing of inherited cancer predisposition. Clin Genet 83(1):2–6. doi:10.1111/cge.12028
Ku CS, Cooper DN, Roukos DH (2013) Clinical relevance of cancer genome sequencing. World J Gastroenterol 19(13):2011–2018. doi:10.3748/wjg.v19.i13.2011
Disclosures
Christof Hottenrott declares that he has no conflict of interest or financial ties to disclose.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hottenrott, C. Laparoscopic resections and ENCODE-guided genomics to advance surgery and oncology. Surg Endosc 28, 2244–2246 (2014). https://doi.org/10.1007/s00464-014-3456-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00464-014-3456-3